Sab Biotherapeutics Inc (SABS)

$3.57 -0.22 (-5.80%)
Market Cap 169.96M
Revenue (ttm) 1.32M
Net Income (ttm) -34.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,584.09%
Debt to Equity Ratio 0.00
Volume 123,800
Avg Vol 361,852
Day's Range N/A - N/A
Shares Out 47.61M
Stochastic %K 7%
Beta 0.59
Analysts Strong Sell
Price Target $9.38

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology
Sector: Healthcare
Phone: 605 679 6980
Address:
777 W 41st St., Miami Beach, United States
JTebow_CWS
JTebow_CWS Feb. 23 at 11:49 AM
$SABS Good video for discussion. https://youtu.be/UGeTKnZK_lw?si=c0ZXblyI8wev-psu
0 · Reply
NeutralFlow
NeutralFlow Feb. 18 at 8:07 AM
$SABS SABS or unknown micro-cap with minimal public information and likely speculative.
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 11:32 PM
$SABS More big money Mark Lampert
2 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 5:16 PM
$SABS
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 5:14 PM
$SABS New institutional investor https://www.rtwfunds.com/our-team/roderick-wong-md/
0 · Reply
Michaelsfl
Michaelsfl Feb. 17 at 3:14 PM
$SABS Stock is dropping, there must be good news coming!!
0 · Reply
Quid_Pro_Quo
Quid_Pro_Quo Feb. 15 at 8:14 AM
$SABS https://finance.yahoo.com/news/sab-biotherapeutics-spotlights-sab-142-060534537.html
1 · Reply
JTebow_CWS
JTebow_CWS Feb. 14 at 2:00 PM
$SABS Munger explains why the board should remain unpaid. https://youtu.be/83F2-8wWujw?si=t4jDEoRk_3h4825D
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 14 at 2:00 PM
$SABS Board members remaining unpaid is key.
0 · Reply
DDiamond_Handz
DDiamond_Handz Feb. 11 at 8:14 PM
$SABS
0 · Reply
Latest News on SABS
SAB BIO to Participate in Upcoming Investor Conferences

Feb 4, 2026, 9:00 AM EST - 19 days ago

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Dec 18, 2025, 8:00 AM EST - 2 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Dec 17, 2025, 8:00 AM EST - 2 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 8, 2025, 8:00 AM EST - 2 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 13, 2025, 5:00 PM EST - 3 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Nov 4, 2025, 8:30 AM EST - 3 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 19, 2025, 7:24 AM EDT - 5 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Sep 3, 2025, 4:05 PM EDT - 6 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Aug 7, 2025, 7:30 AM EDT - 7 months ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Announces Oversubscribed $175 Million Private Placement

Jul 21, 2025, 7:30 AM EDT - 7 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025, 9:00 AM EDT - 10 months ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 31, 2025, 7:32 AM EDT - 11 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 3:40 PM EST - 1 year ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Appoints Lucy To as Chief Financial Officer

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

SAb Biotherapeutics Rebrands as SAB BIO

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

Jun 18, 2024, 1:10 PM EDT - 1 year ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024, 4:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 21, 2024, 7:15 AM EDT - 1 year ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 20, 2024, 5:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Apr 4, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 29, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Mar 25, 2024, 10:15 AM EDT - 2 years ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 23, 2024, 8:00 AM EST - 2 years ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 8:00 AM EST - 2 years ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAB Biotherapeutics Announces Executive Leadership Change

Feb 2, 2024, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Executive Leadership Change

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 23, 2024, 5:58 PM EST - 2 years ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Jan 2, 2024, 4:30 PM EST - 2 years ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 29, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

JTebow_CWS
JTebow_CWS Feb. 23 at 11:49 AM
$SABS Good video for discussion. https://youtu.be/UGeTKnZK_lw?si=c0ZXblyI8wev-psu
0 · Reply
NeutralFlow
NeutralFlow Feb. 18 at 8:07 AM
$SABS SABS or unknown micro-cap with minimal public information and likely speculative.
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 11:32 PM
$SABS More big money Mark Lampert
2 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 5:16 PM
$SABS
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 17 at 5:14 PM
$SABS New institutional investor https://www.rtwfunds.com/our-team/roderick-wong-md/
0 · Reply
Michaelsfl
Michaelsfl Feb. 17 at 3:14 PM
$SABS Stock is dropping, there must be good news coming!!
0 · Reply
Quid_Pro_Quo
Quid_Pro_Quo Feb. 15 at 8:14 AM
$SABS https://finance.yahoo.com/news/sab-biotherapeutics-spotlights-sab-142-060534537.html
1 · Reply
JTebow_CWS
JTebow_CWS Feb. 14 at 2:00 PM
$SABS Munger explains why the board should remain unpaid. https://youtu.be/83F2-8wWujw?si=t4jDEoRk_3h4825D
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 14 at 2:00 PM
$SABS Board members remaining unpaid is key.
0 · Reply
DDiamond_Handz
DDiamond_Handz Feb. 11 at 8:14 PM
$SABS
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 11 at 7:06 PM
$SABS Listen to webcast. https://ir.sab.bio/events/event-details/guggenheim-emerging-outlook-biotech-summit-2026/
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 10 at 11:36 PM
$SABS LETS GO!
1 · Reply
JTebow_CWS
JTebow_CWS Feb. 8 at 12:45 PM
$SABS Still my favorite. I hear and learn something new every time I watch again. Cheaper than plasma centers. https://youtu.be/OlRwqSbOUfo?si=5dEs6nbP4g2yYF9i
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 6 at 6:46 PM
$SABS Page 4-5 Insiders
1 · Reply
JTebow_CWS
JTebow_CWS Feb. 6 at 6:45 PM
$SABS Insiders. Cluster acquiring. 1-3
0 · Reply
Goatcheese
Goatcheese Feb. 6 at 1:44 AM
$SABS got my shares back - lfg
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 5 at 1:17 PM
$SABS Starts at after 6 minute mark. https://podcasts.apple.com/us/podcast/cit1zen-science-by-the-sugar-sciences-podcast/id1826314493?i=1000736725199
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 4 at 9:40 PM
$SABS $SABSW
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 4 at 5:46 PM
$SABS Fire side chats in February. https://www.stocktitan.net/news/SABS/sab-bio-to-participate-in-upcoming-investor-t3wrcgzbjyv2.html
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 3 at 9:50 PM
$SABS Llittle more confirmation bias. https://tipranks.onelink.me/WJho/tqitwh5e
0 · Reply
JTebow_CWS
JTebow_CWS Feb. 3 at 9:49 PM
$SABS Good article https://tipranks.onelink.me/WJho/7vd4c67f
0 · Reply
DDiamond_Handz
DDiamond_Handz Feb. 3 at 8:30 PM
$SABS really thought this would have popped by now but it looks like we are going the slow and steady route
2 · Reply